No 'bacTRAPing' for Takeda: Pharma Snags Envoy for $140M
Three years after its initial investment and two years after inking a research collaboration to discover drugs for schizophrenia, Takeda Pharmaceutical Co. Ltd. found Envoy Therapeutics Inc. irresistible, snagging the privately held company for up to $140 million in cash, including an undisclosed up-front payment and progress-dependent, preclinical milestone payments.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST